|
Kabra Drugs Ltd.
|
Nine Months RESULTS
|
|
|
You can view the
Nine Months Results
for the last 5 years.
|
Market Cap. (Rs.)
|
63.13 Cr.
|
P/BV
|
2.21
|
Book Value (Rs.)
|
12.05
|
|
52 Week High/Low (Rs.)
|
36/11
|
FV/ML
|
10/1
|
P/E(X)
|
0.00
|
|
Bookclosure
|
30/09/2024
|
EPS (Rs.)
|
0.00
|
Div Yield (%)
|
0.00
|
|
(Rs. in Crs.)
| Net Sales/Income from operations | 57.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income From Operations | 57.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Traded Goods | 81.58 | 0.00 | 0.00 | 0.00 | 0.00 |
| Increase/Decrease in Stocks | -30.98 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employees Cost | 1.12 | 0.44 | 0.28 | 0.15 | 0.05 |
| Depreciation | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.66 | 1.04 | 0.09 | 0.05 | 0.08 |
| Total Expenses | 53.41 | 1.48 | 0.37 | 0.20 | 0.13 |
| | | | | | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 3.93 | -1.48 | -0.37 | -0.20 | -0.13 |
| Other Income | 0.38 | 0.00 | 0.00 | 0.01 | 0.00 |
| P/L Before Interest, Excpt. Items & Tax | 4.31 | -1.48 | -0.37 | -0.20 | -0.13 |
| P/L Before Exceptional Items & Tax | 4.31 | -1.48 | -0.37 | -0.20 | -0.13 |
| Exceptional Items | 0.37 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/L Before Tax | 4.67 | -1.48 | -0.37 | -0.20 | -0.13 |
| Tax | 0.77 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/L After Tax from Ordinary Activities | 3.90 | -1.48 | -0.37 | -0.20 | -0.13 |
| Net Profit/Loss For the Period | 3.90 | -1.48 | -0.37 | -0.20 | -0.13 |
| | | | | | |
| Equity Share Capital | 23.71 | 10.08 | 4.39 | 4.39 | 4.39 |
| EPS Before Extra Ordinary * | | | | | |
| Basic EPS (Rs.) | 1.65 | -1.47 | -0.83 | -0.45 | -0.30 |
| Diluted EPS (Rs.) | 1.65 | -1.47 | -0.83 | -0.45 | -0.30 |
| EPS After Extra Ordinary * | | | | | |
| Basic EPS (Rs.) | 1.65 | -1.47 | -0.83 | -0.45 | -0.30 |
| Diluted EPS (Rs.) | 1.65 | -1.47 | -0.83 | -0.45 | -0.30 |
| | | | | | |
| PBITOE Margin (%) | 6.85 | N.A | N.A | N.A | N.A |
| PBTE Margin (%) | 7.50 | N.A | N.A | N.A | N.A |
| PBT Margin (%) | 8.15 | N.A | N.A | N.A | N.A |
| PAT Margin (%) | 6.80 | N.A | N.A | N.A | N.A |
